Bone marrow transplantation for inherited diseases

Current Opinion in Oncology

Volumn 9, Issue 2, 1997, Pages 126-130

  O'Marcaigh, Aengus S ^a   Cowan, Morton J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; THYMOCYTE ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; DISEASE COURSE; DRUG TOXICITY; EARLY DIAGNOSIS; FANCONI ANEMIA; GENETIC DISORDER; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE DEFICIENCY; LYSOSOME STORAGE DISEASE; ORGAN DONOR; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; SICKLE CELL ANEMIA; TREATMENT OUTCOME;

ANEMIA, SICKLE CELL; BETA-THALASSEMIA; BONE MARROW TRANSPLANTATION; FANCONI ANEMIA; GENETIC DISEASES, INBORN; HEMATOLOGIC DISEASES; HUMANS; LYSOSOMAL STORAGE DISEASES; SEVERE COMBINED IMMUNODEFICIENCY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030959109     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (21)

1. Gratwohl A, Hermans J, Baldomero H: Hematopoetic precursor cell transplants in Europe: activity in 1994. Report of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996, 17:137-148. A comprehensive analysis of the indications for bone marrow transplantation in Europe. Important trends are demonstrated by comparison with previous years.
2. Berthet F, Siegrist CA, Ozsahin H, Tuchshmid P, Eich G, Superti-Furga A, Seger RA: Bone marrow transplantation in cartilage-hair hypoplasia: correction of the immunodeficiency but not of the chondrodysplasia. Eur J Pediatr 1996, 155:286-290.
3. Langston AA, Sanders JE, Deeg HJ, Crawford SW, Anasetti C, Sullivan KM, Flowers ME, Storb R: Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996, 92:758-765.
4. Lucarelli, Giardini C, Baronciani D: Bone marrow transplantation in thalassemia. Semin Hematol 1995, 32:297-303. An informative overview of the authors' experience with bone marrow transplantation for homozygous β°-thallassemia in almost 700 cases.
5. Lucarelli G, Clitt RA, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, Andreani M, Manna M, Nesci S, et al.: Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996, 87:2082-2088. A large series that demonstrates improved survival in young patients who were given lower doses of cyclophosphamide. This result is achieved, however, at the expense of an increased graft rejection rate, especially in patients who have received relatively few erythrocyte transfusions prior to transplantation.
6. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, Andreani M, Agostinelli F, Albertini F, Clift RA: Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993, 329:840-844.
7. Andreani M, Manna M, Lucarelli G, Tonucci P, Agostinelli F, Ripalti M, Rapa S, Talevi N, Galimberti M, Nesci S: Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996, 87:3494-3499. An important study describing the evolution and progression of persistent mixed chimerism to full donor engraftment or graft rejection in a significant proportion of patients.
8. Walters MC, Patience M, Leisenring W, Eckman JR, Scott JP, Mentzer WC, Davies SC, Ohene-Frempong K, Bernaudin F, Matthews DC, et al.: Bone marrow transplantation for sickle cell disease. N Engl J Med 1996, 335:369-376. Encouraging results of matched sibling donor BMT for patients with sickle cell disease and significant complications. Avoidable transplant-related cerebrovascular complications were noted. Engraftment was associated with clinical improvement and long-term stabilization of pre-existing cerebrovascular and lung disease.
9. Walters MC, Sullivan KM, Bernaudin F, Souillet G, Vannier JP, Johnson FL, Lenarsky C, Powars D, Bunin N, Ohene-Frempong K, et al.: Neurological complications after allogeneic marrow transplantation for sickle cell anemia. Blood 1995, 85:879-884.
10. Gluckman E, Auerbach AD, Horowitz MM, Sobocinski KA, Ash RC, Bortin MM, Butturini A, Camitta BM, Champlin RE, Friedrich W. et al.: Bone marrow transplantation for Fanconi anemia. Blood 1995, 86:2856-2862. A large study showing a more favorable outcome with matched sibling rather than alternative donors, and an adverse effect of increasing age and lower pretransplantation platelet count on outcome favoring early BMT in the former group.
11. Davies SM, Khan S, Wagner JE, Arthur DC, Auerbach AD, Ramsay NK, Weisdorf DJ: Unrelated donor bone marrow transplantation for Fanconi anemia. Bone Marrow Transplant 1996, 17:43-47.
12. Hoogerbrugge PM, Brouwer OF, Bordigone P, Ringden O, Kapaun P, Onega JJ, O'Meara A, Cornu G, Souillet G, Frappaz D, et al.: Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet 1995, 345:1398-1402.
13. Whitley CB, Belani KG, Chang PN, Summers CG, Blazar BR, Tsai MY, Latchaw RE, Ramsay NK, Kersey JH: Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet 1993, 46:209-218.
14. Peters C, Balthazor M, Shapiro EG, King RJ, Kollman C, Hegland JG, Henslee-Downey J, Trigg ME, Cowan MJ, Sanders J, et al.: Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996, 87:4894-4902. Reports on a significant incidence of GVHD and graft failure or rejection following unrelated BMT. Long-term improvement in cognitive function was observed in selected patients only.
15. Reinherz EL, Geha R, Rappeport JM, Wilson M, Penta AC, Hussey RE, Fitzgerald KA, Daley JF, Levine H, Rosen FS, et al.: Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency. Proc Natl Acad Sci USA 1982, 79:6047-6051.
16. Dror Y, Gallagher R, Wara DW, Colombe BW, Merino A, Benkerrou M, Cowan MJ: Immune reconstitution in severe combined immunodeficiency disease after lectin-treated T-cell-depleted haplocompatible bone marrow transplantation. Blood 1993, 81:2021-2030.
17. Kline RM, Stiehm ER, Cowan MJ:Bone marrow "boosts" following T cell-depleted haploidentical bone marrow transplantation. Bone Marrow Transplant 1996, 17:543-548. Improvement in T-cell immunity demonstrated after marrow reinfusion in patients with suboptimal immunological reconstitution.
18. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E: Allogeneic sibling umbilical cord blood transplantation in children with malignant and non-malignant disease. Lancet 1995, 346:214-219.
19. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P: Placental blood as a source of hematopoetic stem cells for transplantation into unrelated recipients. N Engl J Med 1996, 335:157-166.
20. Wagner JE, Rosenthal J, Sweetman R, Shu XO, Davies SM, RAmsay NK, McGlave PB, Sender L, Cairo MS: Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996, 88:795-802. Reports the outcome of unrelated umbilical cord blood transplantation in 18 patients, most of which were HLA mismatched. A high engraftment rate was found but with a significant delay in platelet engraftment. The occurrence of GVHD compared favorably with that observed after marrow transplantation from similar donors.
21. Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, Hanley ME, Annett G, Brooks JS, El-Khoureiy A, et al.: Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995, 1:1017-1023.